Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.23.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 0 $ 1,884,000
Operating expenses:    
Research and development 10,327,000 9,827,000
General and administrative 19,016,000 21,754,000
Total operating expenses 29,343,000 31,581,000
Operating loss (29,343,000) (29,697,000)
Other income (expense):    
Interest expense (83,000)  
Interest income 213,000 177,000
Loss on sale of debt securities (98,000)  
Royalty income   7,000
Total other income 32,000 184,000
Consolidated net loss from continuing operations (29,311,000) (29,513,000)
Net loss attributable to noncontrolling interest   1,000
Net loss attributable to iBio, Inc. from continuing operations (29,311,000) (29,512,000)
Preferred stock dividends - iBio CDMO Tracking Stock   (88,000)
Net loss available to iBio, Inc. stockholders from continuing operations (29,311,000) (29,600,000)
Loss from discontinued operations (35,699,000) (20,791,000)
Net loss available to iBio, Inc. stockholders (65,010,000) (50,391,000)
Comprehensive loss:    
Consolidated net loss (65,010,000) (50,304,000)
Other comprehensive income (loss) - unrealized gain (loss) on debt securities 180,000 (150,000)
Other comprehensive income - foreign currency adjustment 33,000  
Comprehensive loss $ (64,797,000) $ (50,454,000)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (2.39) $ (3.39)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (2.39) (3.39)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.92) (2.39)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.92) (2.39)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (5.31) (5.78)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (5.31) $ (5.78)
Weighted-average common shares outstanding - basic 12,245 8,721
Weighted-average common shares outstanding - diluted 12,245 8,721